There are breast cancer drugs that Pharmac has assessed to be necessary and will fund if it has enough money. Without a substantial increase to Pharmac’s budget, women are still denied access to these essential treatments.
The $1.774 billion investment won’t cover the 13 new cancer drugs National promised it would fund, or any other new treatment on Pharmac’s Options for Investment list.
Hope is on the horizon for Kiwis with the most aggressive form of breast cancer now that Pharmac’s cancer advisors have recommended pembrolizumab (branded as Keytruda) be funded for both early and advanced triple negative breast cancer (TNBC). Between .